These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 33757667)
1. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China. Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667 [TBL] [Abstract][Full Text] [Related]
2. [Based on a Markov model, cost-effectiveness analysis of influenza vaccination among people aged 60 years and older in Shenzhen]. Wu XL; Ye ZJ; Xie F; Huang DF; Kong TJ; Feng SX; Zhang YW; Jiang Y Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Jul; 43(7):1140-1146. PubMed ID: 35856212 [No Abstract] [Full Text] [Related]
3. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population]. Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044 [No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. You JH; Wong WC; Ip M; Lee NL; Ho SC J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study. Ding H; Huang J; Ngai CH; Sun Q; Kwok KO; Wang HH; Chong M; Wong MC Vaccine; 2022 Feb; 40(9):1282-1288. PubMed ID: 35094867 [TBL] [Abstract][Full Text] [Related]
6. Influenza vaccination for heart failure patients: a cost-effectiveness analysis from the perspective of Chinese healthcare system. Zhao M; Liu F; Wang L; Chen D Front Public Health; 2024; 12():1348207. PubMed ID: 39185111 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414 [TBL] [Abstract][Full Text] [Related]
8. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis. Brydak L; Roiz J; Faivre P; Reygrobellet C Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294 [TBL] [Abstract][Full Text] [Related]
9. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K. Meier G; Gregg M; Poulsen Nautrup B J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. Lin CJ; Zimmerman RK; Smith KJ Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777 [TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study. Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857 [TBL] [Abstract][Full Text] [Related]
17. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Kuhlmann A; von der Schulenburg JG Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404 [TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China]. Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135 [No Abstract] [Full Text] [Related]
19. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China. Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y Front Public Health; 2021; 9():647725. PubMed ID: 34109145 [No Abstract] [Full Text] [Related]
20. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis. Xing N; Cheung WY; Jiang M; You JHS Am J Infect Control; 2019 Nov; 47(11):1302-1308. PubMed ID: 31266663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]